Cargando…

Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (The Covid-19 pandemic) strains health care capacity. Better risk stratification, with discharge of patients with a predicted mild disease trajectory, can ease this burden. Elevated blood-soluble urokinase plasminogen activator receptor (su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stauning, Marius Ahm, Altintas, Izzet, Kallemose, Thomas, Eugen-Olsen, Jesper, Lindstrøm, Mette Bendtz, Rasmussen, Line Jee Hartmann, Gamst-Jensen, Hejdi, Nehlin, Jan O., Andersen, Ove, Tingleff, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Clinical Laboratory Emergency Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997406/ https://www.ncbi.nlm.nih.gov/pubmed/34092446 http://dx.doi.org/10.1016/j.jemermed.2021.03.012

Ejemplares similares

suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19
por: Altintas, Izzet, et al.
Publicado: (2021)

Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease
por: Iversen, Esben, et al.
Publicado: (2022)

Risk Factors Associated with Serum Levels of the Inflammatory Biomarker Soluble Urokinase Plasminogen Activator Receptor in a General Population
por: Haupt, Thomas H, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2021)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy
por: Schultz, Martin, et al.
Publicado: (2019)

COVID-19 mortality among selective serotonin reuptake inhibitor users—results from a nationwide cohort
por: Stauning, Marius Ahm, et al.
Publicado: (2023)

Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2016)

Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis
por: Petersen, Jens Emil Vang, et al.
Publicado: (2020)

Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study*
por: Rasmussen, Line J. H., et al.
Publicado: (2018)

Associations between degree-of-worry, self-rated health and acute hospitalisation after contacting a medical helpline: a Danish prospective cohort study
por: Jensen, Andrea Nedergaard, et al.
Publicado: (2021)

Self-rated health and chronic inflammation are related and independently associated with hospitalization and long-term mortality in the general population
por: Tavenier, Juliette, et al.
Publicado: (2022)

Relation between illness representation and self-reported degree-of-worry in patients calling out-of-hours services: a mixed-methods study in Copenhagen, Denmark
por: Thilsted, Sita LeBlanc, et al.
Publicado: (2018)

Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis
por: Butt, Sheraz, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

In-Vitro Study of Urokinase Thrombolysis Following Stereotactic Aspiration of Intracerebral Hematoma
por: Son, Wonsoo, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Sociodemographic and health-related determinants for making repeated calls to a medical helpline: a prospective cohort study
por: Blakoe, Mitti, et al.
Publicado: (2019)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
por: Höybye, Charlotte, et al.
Publicado: (2019)

Healthy lifestyles reduce suPAR and mortality in a Danish general population study
por: Haupt, Thomas Huneck, et al.
Publicado: (2019)

Ability of combined soluble urokinase plasminogen activator receptor to predict preventable emergency attendance in older patients in Japan: a prospective pilot study
por: Mitsunaga, Toshiya, et al.
Publicado: (2022)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
por: Rotbain Curovic, Viktor, et al.
Publicado: (2022)

Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients
por: Iversen, Esben, et al.
Publicado: (2020)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor
por: Dowsett, Joseph, et al.
Publicado: (2021)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
por: Gumus, Aziz, et al.
Publicado: (2015)

Short Communication: Opportunities and Challenges for Early Person-Centered Care for Older Patients in Emergency Settings
por: Jensen, Andrea N., et al.
Publicado: (2021)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

Extracellular Matrix Biomarker, Fibulin-1, Is Closely Related to NT-proBNP and Soluble Urokinase Plasminogen Activator Receptor in Patients with Aortic Valve Stenosis (The SEAS Study)
por: Kruger, Ruan, et al.
Publicado: (2014)

Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study
por: Kofoed, Kristian, et al.
Publicado: (2007)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_i469832fgp5id26lhc6ct44cgf